Benzinga | Apr 29, 2021 10:42AM EDT

Dr. Reddy's Laboratories Announces Launch Of Albendazole Tablets, USP In US

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's")) today announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Albenza brand and generic had U.S. sales of approximately $27 million MAT for the most recent twelve months ending in November 2020 according to IQVIA Health*.